Venkatesh Ravula, Venkanna Muripiti, Akash Kumar, Li-Fang Wang, Praveen Kumar Vemula, Srilakshmi V Patri
The liposomal systems proved remarkably useful for the delivery of genetic materials but enhancing their efficacy remains a significant challenge. While structural alterations could result in the discovery of more effective transfecting lipids, improving the efficacy of widely used lipid carriers is also crucial in order to compete with viral vectors for gene delivery. Herein, we developed formulations of commercially available lipid, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) with synthetic amino acid based cationic lipids. Two cationic lipids were synthesized using amino acids, with either cystine (CTT) or arginine (AT) in the head group. These lipids were used to formulate co-liposomal structures with different lipid compositions. The liposomal formulations were broadly categorised into two types: amino acid-based liposomes without DOTAP (CTTD and ATD) and those with DOTAP (DtATD and DtCTTD). Optimized lipid-DNA complexes of DOTAP-incorporated formulations (DtATD and DtCTTD) exhibited enhanced efficacy in transfection compared to formulations lacking DOTAP as well as commercial formulations such as DOTAP:DOPE. Notably, DtCTTD displayed superior transfection capabilities in prostate cancer (PC3) and lung cancer (A549) cell lines when compared to the widely used commercial transfection reagent, Lipofectamine. Collectively, the findings from this study suggest that DOTAP-incorporated formulations derived from amino acid-based liposomes, hold promise as effective tools for improving transfection efficacy with reduced toxicity, offering potential advancements in gene delivery applications.
{"title":"DOTAP Modified Formulations of Aminoacid Based Cationic Liposomes for Improved Gene Delivery and Cell Viability.","authors":"Venkatesh Ravula, Venkanna Muripiti, Akash Kumar, Li-Fang Wang, Praveen Kumar Vemula, Srilakshmi V Patri","doi":"10.1002/cmdc.202400324","DOIUrl":"10.1002/cmdc.202400324","url":null,"abstract":"<p><p>The liposomal systems proved remarkably useful for the delivery of genetic materials but enhancing their efficacy remains a significant challenge. While structural alterations could result in the discovery of more effective transfecting lipids, improving the efficacy of widely used lipid carriers is also crucial in order to compete with viral vectors for gene delivery. Herein, we developed formulations of commercially available lipid, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) with synthetic amino acid based cationic lipids. Two cationic lipids were synthesized using amino acids, with either cystine (CTT) or arginine (AT) in the head group. These lipids were used to formulate co-liposomal structures with different lipid compositions. The liposomal formulations were broadly categorised into two types: amino acid-based liposomes without DOTAP (CTTD and ATD) and those with DOTAP (DtATD and DtCTTD). Optimized lipid-DNA complexes of DOTAP-incorporated formulations (DtATD and DtCTTD) exhibited enhanced efficacy in transfection compared to formulations lacking DOTAP as well as commercial formulations such as DOTAP:DOPE. Notably, DtCTTD displayed superior transfection capabilities in prostate cancer (PC3) and lung cancer (A549) cell lines when compared to the widely used commercial transfection reagent, Lipofectamine. Collectively, the findings from this study suggest that DOTAP-incorporated formulations derived from amino acid-based liposomes, hold promise as effective tools for improving transfection efficacy with reduced toxicity, offering potential advancements in gene delivery applications.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Morane Beaumet, Leticia M Lazinski, Marc Maresca, Romain Haudecoeur
Tyrosinases (TYRs) are copper-containing metalloenzymes present in a large diversity of species. In human, hTYR is responsible for pivotal steps in melanogenesis, catalysing the oxidation of l-tyrosine to l-DOPA and further to dopaquinone. While numerous TYR inhibitors have been reported, polyphenolic compounds tend to dominate the literature. However, many of these compounds, particularly monophenols and catechols, have been identified as alternative substrates rather than true inhibitors, given their structural similarity to natural substrates. Resorcinol-containing compounds have emerged as promising candidates to address this challenge, as the meta-dihydroxy moiety in resorcinol demonstrates resistance to TYR-mediated oxidation, while retaining the favourable interactions with copper ions provided by the hydroxy groups. Although their precise mechanism of action remains debated, resorcinol derivatives have yielded some of the most active compounds against isolated mushroom and human TYRs, as well as clinically used dermocosmetic agents like rucinol and thiamidol, which exhibited very promising effects in patients with facial melasma. This review outlines the development of resorcinol-containing TYR inhibitors, categorized by scaffold type, ranging from simple alkyl analogues to intricate synthetic derivatives. Mechanistic insights about the resorcinol-TYR interaction are also presented and debated.
{"title":"Tyrosinase Inhibition and Antimelanogenic Effects of Resorcinol-Containing Compounds.","authors":"Morane Beaumet, Leticia M Lazinski, Marc Maresca, Romain Haudecoeur","doi":"10.1002/cmdc.202400314","DOIUrl":"10.1002/cmdc.202400314","url":null,"abstract":"<p><p>Tyrosinases (TYRs) are copper-containing metalloenzymes present in a large diversity of species. In human, hTYR is responsible for pivotal steps in melanogenesis, catalysing the oxidation of l-tyrosine to l-DOPA and further to dopaquinone. While numerous TYR inhibitors have been reported, polyphenolic compounds tend to dominate the literature. However, many of these compounds, particularly monophenols and catechols, have been identified as alternative substrates rather than true inhibitors, given their structural similarity to natural substrates. Resorcinol-containing compounds have emerged as promising candidates to address this challenge, as the meta-dihydroxy moiety in resorcinol demonstrates resistance to TYR-mediated oxidation, while retaining the favourable interactions with copper ions provided by the hydroxy groups. Although their precise mechanism of action remains debated, resorcinol derivatives have yielded some of the most active compounds against isolated mushroom and human TYRs, as well as clinically used dermocosmetic agents like rucinol and thiamidol, which exhibited very promising effects in patients with facial melasma. This review outlines the development of resorcinol-containing TYR inhibitors, categorized by scaffold type, ranging from simple alkyl analogues to intricate synthetic derivatives. Mechanistic insights about the resorcinol-TYR interaction are also presented and debated.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nowadays, the widespread diffusion of infections caused by opportunistic fungi represents a demanding threat for global health security. This phenomenon has also worsened by the emergence of contagious events in hospitalisation environments and by the fact that many fungi have developed harsh and serious resistance mechanisms to the traditional antimycotic drugs. Hence, the design of novel antifungal agents is a key factor to counteract mycotic infections and resistance. Within this context, nanomaterials are gaining increasing attention thanks to their biocidal character. Among these, carbon dots (CDs) represent a class of zero-dimensional, photoluminescent and quasi-spherical nanoparticles which, for their great and tuneable features, have found applications in catalysis, sensing and biomedicine. Nevertheless, only a few works define and recapitulate their antifungal properties. Therefore, we aim to give an overview about the recent advances in the synthesis of CDs active against infective fungi. We described the general features of CDs and fungal cells, by highlighting some of the most common antimycotic mechanisms. Then, we evaluated the effects of CDs, antimicrobial drugs-loaded CDs and CDs-incorporated packaging systems on different fungi and analysed the use of CDs as fluorescent nano-trackers for bioimaging, showing, to all effects, their promising application as antifungal agents.
如今,由机会性真菌引起的感染广泛传播,对全球健康安全构成了严重威胁。住院环境中传染病的出现,以及许多真菌对传统抗真菌药物产生了苛刻而严重的抗药性机制,也加剧了这一现象。因此,设计新型抗真菌剂是应对真菌感染和抗药性的关键因素。在此背景下,纳米材料因其杀菌特性而日益受到关注。其中,碳点(CD)是一类零维、光致发光、准球形的纳米粒子,由于其巨大的可调特性,已被应用于催化、传感和生物医学领域。然而,只有少数几项研究确定并再现了它们的抗真菌特性。因此,我们旨在概述最近在合成对感染性真菌具有活性的光盘方面取得的进展。通过强调一些最常见的抗真菌机制,我们描述了 CD 和真菌细胞的一般特征。然后,我们评估了光盘、载入抗菌药物的光盘和加入光盘的包装系统对不同真菌的影响,并分析了将光盘作为荧光纳米追踪器用于生物成像的情况,结果表明它们作为抗真菌剂的应用前景广阔。
{"title":"Carbon Dots as Bioactive Antifungal Nanomaterials.","authors":"Elisa Sturabotti, Alessandro Camilli, Francesca Leonelli, Fabrizio Vetica","doi":"10.1002/cmdc.202400463","DOIUrl":"https://doi.org/10.1002/cmdc.202400463","url":null,"abstract":"<p><p>Nowadays, the widespread diffusion of infections caused by opportunistic fungi represents a demanding threat for global health security. This phenomenon has also worsened by the emergence of contagious events in hospitalisation environments and by the fact that many fungi have developed harsh and serious resistance mechanisms to the traditional antimycotic drugs. Hence, the design of novel antifungal agents is a key factor to counteract mycotic infections and resistance. Within this context, nanomaterials are gaining increasing attention thanks to their biocidal character. Among these, carbon dots (CDs) represent a class of zero-dimensional, photoluminescent and quasi-spherical nanoparticles which, for their great and tuneable features, have found applications in catalysis, sensing and biomedicine. Nevertheless, only a few works define and recapitulate their antifungal properties. Therefore, we aim to give an overview about the recent advances in the synthesis of CDs active against infective fungi. We described the general features of CDs and fungal cells, by highlighting some of the most common antimycotic mechanisms. Then, we evaluated the effects of CDs, antimicrobial drugs-loaded CDs and CDs-incorporated packaging systems on different fungi and analysed the use of CDs as fluorescent nano-trackers for bioimaging, showing, to all effects, their promising application as antifungal agents.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prof. PharmD. Rebecca Deprez-Poulain, Dr. Maria Duca, Dr. Nicolas George, Dr. Benoit Deprez, Dr. Jean-Yves Ortholand
The French Society of Medicinal Chemistry or “ Société de Chimie Thérapeutique ” (SCT) was founded in 1966. Since its inception, its mission has been to promote knowledge in the main fields of pharmaceutical research and development, in particular the research and validation of biological targets of therapeutic interest, the screening, design and optimization of drug candidates, chemical biology, medicinal chemistry, pharmacokinetics, metabolism and toxicity. Since 1964, the Society has organized an annual international congress (RICT), and later thematic days for young researchers and workshops on specific topics. The SCT is also a member of the European Federation for Medicinal Chemistry (EFMC) and organized the International Symposium on Medicinal Chemistry (ISMC) in Nice in 2022. Several new trends can be identified in the activities of the SCT, such as the organization of regular webinars, but also the recent creation of the Young MedChem Forum, as well as the distribution of a newsletter reporting scientific achievements in the French community and abroad, and an improved presence on social networks. These trends are in line with the current changes in the field in terms of scientific progress, means of communication in the community and with the public and inclusiveness.
{"title":"The French Medicinal Chemistry Society–SCT, an Historical Member of EFMC**","authors":"Prof. PharmD. Rebecca Deprez-Poulain, Dr. Maria Duca, Dr. Nicolas George, Dr. Benoit Deprez, Dr. Jean-Yves Ortholand","doi":"10.1002/cmdc.202400437","DOIUrl":"10.1002/cmdc.202400437","url":null,"abstract":"<p>The French Society of Medicinal Chemistry or “ Société de Chimie Thérapeutique ” (SCT) was founded in 1966. Since its inception, its mission has been to promote knowledge in the main fields of pharmaceutical research and development, in particular the research and validation of biological targets of therapeutic interest, the screening, design and optimization of drug candidates, chemical biology, medicinal chemistry, pharmacokinetics, metabolism and toxicity. Since 1964, the Society has organized an annual international congress (RICT), and later thematic days for young researchers and workshops on specific topics. The SCT is also a member of the European Federation for Medicinal Chemistry (EFMC) and organized the International Symposium on Medicinal Chemistry (ISMC) in Nice in 2022. Several new trends can be identified in the activities of the SCT, such as the organization of regular webinars, but also the recent creation of the Young MedChem Forum, as well as the distribution of a newsletter reporting scientific achievements in the French community and abroad, and an improved presence on social networks. These trends are in line with the current changes in the field in terms of scientific progress, means of communication in the community and with the public and inclusiveness.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202400437","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
New 4-nitrobenzyl derivatives were designed and synthesised by nucleophilic substitution reactions of 4-nitrobenzyl bromide with malonic acid and its derivatives. The synthesised molecules were characterised using mass analysis and spectroscopic techniques and tested for their antioxidant properties using various methods, such as nitric oxide, DPPH, and hydrogen peroxide radical scavenging methods. The anti-inflammatory activities of the molecules were assessed using RBC membrane stabilisation and albumin denaturation methods. We evaluated the compounds' potential anti-prostate cancer activity using the DU145 cell line. The MTT assay determined the cell viability, indicating good anti-proliferative activity. The molecule 3 c exhibited the highest potency, with a CTC50 of 11.83 μg/mL. Molecular dynamics simulations were performed to study the stability of the ligand within the protein after docking and the resulting protein-ligand complex. The in vivo analysis of molecule 3 c in the DAL xenograft model demonstrated promising results. The increase in life span, reduction in tumor volume, and comparable effects to standard drugs are encouraging features that suggest that molecule 3 c may possess significant potential as an anti-cancer agent. The research also implies that these molecules might be potential lead compounds for developing new prostate cancer drugs.
{"title":"Design, Synthesis, and Anti-Prostate Cancer Potential of 2-(4-Nitrobenzyl) Malonates In Vitro and DAL Acute Oral Toxicity Assessment In Vivo.","authors":"Bharathi Hassan Ganesh, Baladhandapani Aruchamy, Srikrishna Mudradi, Sarthak Mohanty, Himabindu Padinjarathil, Simone Carradori, Prasanna Ramani","doi":"10.1002/cmdc.202400371","DOIUrl":"10.1002/cmdc.202400371","url":null,"abstract":"<p><p>New 4-nitrobenzyl derivatives were designed and synthesised by nucleophilic substitution reactions of 4-nitrobenzyl bromide with malonic acid and its derivatives. The synthesised molecules were characterised using mass analysis and spectroscopic techniques and tested for their antioxidant properties using various methods, such as nitric oxide, DPPH, and hydrogen peroxide radical scavenging methods. The anti-inflammatory activities of the molecules were assessed using RBC membrane stabilisation and albumin denaturation methods. We evaluated the compounds' potential anti-prostate cancer activity using the DU145 cell line. The MTT assay determined the cell viability, indicating good anti-proliferative activity. The molecule 3 c exhibited the highest potency, with a CTC<sub>50</sub> of 11.83 μg/mL. Molecular dynamics simulations were performed to study the stability of the ligand within the protein after docking and the resulting protein-ligand complex. The in vivo analysis of molecule 3 c in the DAL xenograft model demonstrated promising results. The increase in life span, reduction in tumor volume, and comparable effects to standard drugs are encouraging features that suggest that molecule 3 c may possess significant potential as an anti-cancer agent. The research also implies that these molecules might be potential lead compounds for developing new prostate cancer drugs.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lian Xue, Dr. Caitlin V. M. L. Jie, Dr. Sandrine Desrayaud, Dr. Yves P. Auberson
The Front Cover shows the clinical demands that drive the development of novel imaging agents for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Multiple pathways lead from the initial concept to a practically useful compound. The process for the discovery and development of imaging agents follows a well-documented path; however, variations are possible and provide some flexibility depending on the resources and technologies available to the project team. According to the question asked, the properties of the imaging agents will vary, and the requirements for their development will differ. Understanding the target profile required to address the clinical questions, as well as the possible steps enabling the discovery, optimization, and validation of imaging agents is critical. Like when climbing a mountain, resource efficiency and speed should be optimized to guarantee the optimal development of novel imaging agent candidates. More details can be found in article 10.1002/cmdc.202400094 by Yves P. Auberson and co-workers.